Xenter announces new Therapeutics Business Unit; taps David Bearss to lead On June 23, 2021, following the close of $12 million in Series A funding, Xenter announced the launch of the Xenter Therapeutics business unit. This new unit will be led by David J. Bearss PhD, Xenter’s president and
by Mark Tullis
Jump raised $80 million in a Series B led by Insight Partners, bringing total funding to $105 million. The wealthtech startup is expanding from AI meeting automation into an enterprise-grade AI operating layer for financial advisory firms.
At Silicon Slopes Summit 2026, Mark Cuban and CMS Administrator Chris Klomp confronted the real drivers of healthcare costs—complexity, consolidation, and hidden incentives—in a candid discussion on transparency, competition, and why meaningful reform remains so hard.
Matt Memmott, CEO of AlphaTech Research Corp. (American Fork, UT) is pioneering molten salt reactors—compact, safe nuclear units that could stabilize grids, power industry, complement renewables, and transform nuclear waste into valuable resources.